CRISPR Therapeutics AG
CRSPNasdaqCIK 1674416HealthcareFiscal year ends Dec 31
All transactions: 9
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
No open-market purchases or sales by insiders are in coverage from Dec 2024 to Nov 2026.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2018-12-27 | Vertex Pharmaceuticals (Europe) Ltd10% owner | Purchase | 27,461 | $24.9487 | $685.1k | Form 4 |
| 2018-12-26 | Vertex Pharmaceuticals (Europe) Ltd10% owner | Purchase | 12,737 | $24.8942 | $317.1k | Form 4 |
| 2018-12-24 | Vertex Pharmaceuticals (Europe) Ltd10% owner | Purchase | 53,655 | $24.9687 | $1.3m | Form 4 |
| 2018-12-24 | Vertex Pharmaceuticals (Europe) Ltd10% owner | Purchase | 11,742 | $23.1766 | $272.1k | Form 4 |
| 2018-12-24 | Vertex Pharmaceuticals (Europe) Ltd10% owner | Purchase | 2,603 | $22.9147 | $59.6k | Form 4 |
| 2018-12-21 | Vertex Pharmaceuticals (Europe) Ltd10% owner | Purchase | 22,742 | $22.5784 | $513.5k | Form 4 |
| 2016-10-24 | Glaxosmithkline plc10% owner | Purchase | 66,500 | $14.00 | $931.0k | Form 4 |
| 2016-10-24 | Glaxosmithkline plc10% owner | Conversion | 211,567 | not reported | not reported | Form 4 |
| 2016-10-24 | Glaxosmithkline plc10% owner | Conversion | 2,942,560 | not reported | not reported | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Nov 2, 2026, 17:00 ET. Listed shows no prices and gives no investment advice.